Oxford BioTherapeutics appoints C. Glenn Begley as a senior clinical advisor

pharmafile | January 17, 2012 | Appointment | Business Services, Research and Development, Sales and Marketing C. Glenn Begley, Oxford Biotherapeutics 

Oxford BioTherapeutics has appointed C. Glenn Begley as a senior clinical advisor and non-executive director of the firm. 

Dr Begley, who was the vice president and global head of haematology and oncology research at Amgen, will help shape and execute OBT’s clinical and corporate strategy as it advances its pipeline of oncology antibody-based drugs into clinical development.

Dr Begley has over 10 years of experience in leading the strategy and co-ordination of oncology research at Amgen, and brings extensive knowledge and expertise to OBT at an exciting phase in the company’s development. 

Before joining Amgen in 2002, he gained over 20 years of clinical experience in medical oncology and haematology. 

Advertisement

He has held several academic positions, including: executive director at the Western Australian Institute of Medical Research, senior principal research fellow and professor of medicine at the University of Melbourne at Walter and Eliza Hall Institute of Medical Research.  

Related Content

Tech platform company WuXi Biologics inks deal with cancer specialist Oxford BioTherapeutics worth $450m

Clinical stage oncology firm Oxford BioTherapeutics has signed a deal with the open-access biologics technology …

Sanofi buys into cancer antibody research

Sanofi-Aventis has bought a global licence to develop and commercialise one of Oxford BioTherapeutics’ (OBT) …

GSK signs oncology deal with UK biotech

GSK has struck a deal with Oxford BioTherapeutics to develop therapies for primary, metastatic and …

The Gateway to Local Adoption Series

Latest content